所有图片(4)

主要文件

查看所有文档

R116

利鲁唑

Name: 利鲁唑
Brand: SIGMA
Price: 4239.58 CNY

≥98% (HPLC), solid, glutamate release inhibitor

别名:

2-氨基-6-（三氟甲氧基）苯并噻唑

登录查看公司和协议定价

选择尺寸

100 μL

¥4,239.58

请联系客服了解存货情况

新价格，新优惠！

获取大包装报价

所有图片(4)

选择尺寸

变更视图

100 μL

¥4,239.58

About This Item

经验公式（希尔记法）:

C₈H₅F₃N₂OS

CAS号:

1744-22-5

分子量:

234.20

MDL编号:

MFCD00210213

UNSPSC代码:

12352200

PubChem化学物质编号:

24278006

NACRES:

NA.77

¥4,239.58

请联系客服了解存货情况

新价格，新优惠！

获取大包装报价

比较类似商品

查看完整比较结果

显示差异

1 of 4

此商品	557324	B9934	G9420
R116 利鲁唑	557324 Riluzole	B9934 BTA-1	G9420 GNF-2
form solid	form solid	form solid	form solid
Quality Level 100	Quality Level 100	Quality Level 100	Quality Level 100
originator Sanofi Aventis	originator -	originator -	originator -
Gene Information human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335) rat ... Scnn1g(24768)	Gene Information -	Gene Information human ... APP(351)	Gene Information -

生化/生理作用

谷氨酸释放抑制剂；抗惊厥

特点和优势

该化合物在受体分类和信号转导手册的钾通道页面上有重点介绍。想要浏览手册的其他页面，请单击此处。

该化合物是由赛诺菲安万特开发的。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单，请单击此处。

象形图

GHS06

警示用语：

Danger

危险声明

H300

预防措施声明

P301 + P310 + P330

危险分类

Acute Tox. 2 Oral

储存分类代码

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

个人防护装备

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

技术规格说明书

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Predictions and experimental tests of a new biophysical model of the mammalian respiratory oscillator.

Ryan S Phillips et al.

eLife, 11 (2022-07-08)

Previously our computational modeling studies (Phillips et al., 2019) proposed that neuronal persistent sodium current (INaP) and calcium-activated non-selective cation current (ICAN) are key biophysical factors that, respectively, generate inspiratory rhythm and burst pattern in the mammalian preBötzinger complex (preBötC)

Riluzole, neuroprotection and amyotrophic lateral sclerosis.

B C Cheah et al.

Current medicinal chemistry, 17(18), 1942-1199 (2010-04-10)

Amyotrophic lateral sclerosis (ALS) is a universally fatal neurodegenerative disease of the human motor system. Aetiological mechanisms implicated in the development of ALS have been linked to the glutamatergic neurotransmitter system, with destruction of motor neurons triggered through excessive activation

A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?

Mark C Bellingham

CNS neuroscience & therapeutics, 17(1), 4-31 (2010-03-20)

Amyotrophic lateral sclerosis (ALS) is a devastating and fatal neurodegenerative disease of adults which preferentially attacks the neuromotor system. Riluzole has been used as the only approved treatment for amyotrophic lateral sclerosis since 1995, but its mechanism(s) of action in

Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole.

Gwen Schwartz et al.

Progress in brain research, 137, 177-190 (2002-11-21)

Traumatic spinal cord injury is a consequence of a primary mechanical insult and a sequence of progressive secondary pathophysiological events that confound efforts to mitigate neurological deficits. Pharmacotherapy aimed at reducing the secondary injury is limited by a narrow therapeutic

Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis.

Steve Vucic et al.

Brain : a journal of neurology, 136(Pt 5), 1361-1370 (2013-04-26)

Riluzole, a benzothiazole derivative, has been shown to be effective in prolonging survival in amyotrophic lateral sclerosis. The mechanisms by which riluzole exerts neuroprotective effects in amyotrophic lateral sclerosis remains to be fully elucidated, although inhibition of glutamatergic transmission and

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持

主要文件

利鲁唑

≥98% (HPLC), solid, glutamate release inhibitor

选择尺寸

选择尺寸

About This Item

推荐产品

属性

产品名称

表单

质量水平

创始人

SMILES字符串

InChI

InChI key

基因信息

比较类似商品

此商品

说明

生化/生理作用

特点和优势

安全信息

象形图

警示用语：

危险声明

预防措施声明

危险分类

储存分类代码

WGK

个人防护装备

文件

分析证书(COA)

已有该产品？

同行评审论文

技术服务